Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
Meeting ReportOncology - Basic: Therapy, Metrics and Intervention

Radioiodine therapy for metastatic differentiated thyroid cancer: Determination of the maximum safe dose until 48 hours after the administration of a tracer dose

J Willegaignon, VPB Ribeiro, MT Sapienza and CA Buchpiguel
Journal of Nuclear Medicine May 2009, 50 (supplement 2) 1638;
J Willegaignon
1Nuclear Medicine Center - FMUSP, Sao Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
VPB Ribeiro
1Nuclear Medicine Center - FMUSP, Sao Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MT Sapienza
1Nuclear Medicine Center - FMUSP, Sao Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CA Buchpiguel
1Nuclear Medicine Center - FMUSP, Sao Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

1638

Objectives In radioiodine therapy for differentiated thyroid cancer, the maximum safe dose (MSD) to be administered to patients is based on considering an absorbed dose limit of 2-3Gy in bone marrow and maximum body retention of 120mCi at 48h. The objective of this study is to compare the calculated MSD considering the tracer dose kinetic in a study of 96h versus study of 48h.

Methods 39 patients with differentiated thyroid cancer and treated with MSD were included in this retrospective study. The iodine-131 retention rates in the blood and whole-body were measured at 0, 4, 24, 48, 72, and 96h after tracer dose administration with additional measurement of whole-body after 2h. MIRD methodology was used in order to estimate the absorbed dose in bone marrow. The MSD was limited with radiation of 2Gy and 3Gy to the bone marrow and whole-body retention of 120mCi at 48h.

Results The mean tracer administered dose was 2.16mCi. The average retention rate of iodine-131 in the blood samples at 24, 48, 72 e 96 h were 2.9%, 1.0%, 0.5% e 0.3%, and in the whole-body was 30%, 13%, 6% e 4%. The mean absorbed dose in bone marrow was 6.3mGy/mCi in the study of 96h, and 5.2mGy/mCi in 48h. The average of MSD was 624mCi to the limit of 2Gy in bone marrow, and 839mCi to 3Gy. The ratio between the MSD using the study of 48h to 96h was 1.12 to the limit of 2Gy and 0.86 to 3Gy.

Conclusions The tracer activity kinetic study of 48h demonstrated to be comparable to the study of 96h for the largest safe dose determination.

  • © 2009 by Society of Nuclear Medicine
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 50, Issue supplement 2
May 2009
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Radioiodine therapy for metastatic differentiated thyroid cancer: Determination of the maximum safe dose until 48 hours after the administration of a tracer dose
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Radioiodine therapy for metastatic differentiated thyroid cancer: Determination of the maximum safe dose until 48 hours after the administration of a tracer dose
J Willegaignon, VPB Ribeiro, MT Sapienza, CA Buchpiguel
Journal of Nuclear Medicine May 2009, 50 (supplement 2) 1638;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Radioiodine therapy for metastatic differentiated thyroid cancer: Determination of the maximum safe dose until 48 hours after the administration of a tracer dose
J Willegaignon, VPB Ribeiro, MT Sapienza, CA Buchpiguel
Journal of Nuclear Medicine May 2009, 50 (supplement 2) 1638;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oncology - Basic: Therapy, Metrics and Intervention

  • Radioimmunotherapy (RIT) with anti-CD45 antibody: Optimal timing of the preload
  • Preliminary study of a biodegradable seed: 32P-chromic phosphate-poly (L-lactide) on its biodegradation, pharmacokinetics of 32P nanoparticles after intratumor implantation
  • SUV analysis underestimates antitumor activity of a new drug
Show more Oncology - Basic: Therapy, Metrics and Intervention

Therapy Metrics and Intervention Posters

  • The impact of PET/CT in radiotherapy treatment planning
  • Radioimmunotherapy of EGFR-positive tumors with 90Y-labeled panitumumab
  • FDG-PET based GTVs for radiotherapy planning of lung cancer: Is there any influence of registration method on volume size?
Show more Therapy Metrics and Intervention Posters

Similar Articles

SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire